Integrated Core Strategies (US) LLC 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-01-19 4:10 pm Sale |
2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Integrated Core Strategies (US) LLC | 79,363 3.700% |
-27,266 (-25.57%) |
Filing |
| 2022-07-19 4:08 pm Purchase |
2022-07-18 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Integrated Core Strategies (US) LLC | 106,629 5.000% |
1,058 (+1.00%) |
Filing |
| 2022-07-15 4:04 pm Sale |
2022-07-07 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Integrated Core Strategies (US) LLC | 105,571 4.970% |
-269 (-0.25%) |
Filing |
| 2022-07-07 4:56 pm Purchase |
2022-06-27 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Integrated Core Strategies (US) LLC | 105,840 4.980% |
105,840 (New Position) |
Filing |